C/EBPα or C/EBPα oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-κB p50 bound to the bcl-2 and FLIP gene promoters

Leukemia

Volumn 23, Issue 2, 2009, Pages 365-374

  Paz Priel, I ^a   Ghosal, A K ^a   Kowalski, J ^a   Friedman, A D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CCAAT ENHANCER BINDING PROTEIN ALPHA; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROTECTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; SPLEEN CELL; TRANSGENE; PHYSIOLOGY;

CCAAT-ENHANCER-BINDING PROTEIN-ALPHA;

EID: 60149087551     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.297     Document Type: Article

References (41)

1. Friedman AD, McKnight SL. Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Dev 1990; 4: 1416-1426.
2. Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 1988; 240: 1759-1764.
3. Landschulz WH, Johnson PF, McKnight SL. The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite. Science 1989; 243 1681-1688.
4. Friedman AD. Transcriptional control of granulocyte and monocyte development. Oncogene 2007; 26: 6816-6828.
5. Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992; 80: 1725-1735.
6. Wang D, D'Costa J, Civin CI, Friedman AD. C/EBPα directs monocytic commitment of primary myeloid progenitors. Blood 2006; 108: 1223-1229.
7. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569-574.
8. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity 2004; 21: 853-863.
9. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633.
10. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH et al. Mutations in the gene encoding the transcription factor CCAAT/ enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332-1340.
11. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270.
12. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717-2723.
13. Liang DC, Shih LY, Huang CF, Hung IJ, Yang CP, Liu HC et al. CEBPα mutations in childhood acute myeloid leukemia. Leukemia 2005; 19: 410-414.
14. Cleaves R, Wang QF, Friedman AD. C/EBPαp30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding. Oncogene 2004; 23: 716-725.
15. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/ EBPα in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
16. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood 2004; 103: 1883-1890.
17. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K et al. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
18. Pabst T, Mueller BU. Transcriptional dysregulation during myeloid transformation in AML. Oncogene 2007; 26: 6829-6837.
19. Paz-Priel I, Cai DH, Wang D, Kowalski J, Blackford A, Liu H et al. CCAAT/enhancer binding protein α (C/EBPα) and C/EBPα myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-κB p50. Mol Cancer Res 2005; 3: 585-596.
20. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81 3091-3096.
21. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101: 2125-2131.
22. Del Princip MI, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Mazzone C et al. Apoptosis and immaturity in acute myeloid leukemia. Hematology 2005; 10: 25-34.
23. Meyer LH, Queudeville M, Eckhoff SM, Creutzig U, Reinhardt D, Karawajew L et al. Intact apoptosis signalling in myeloid leukaemia cells determines treatment outcome in childhood AML. Blood 2008; 111 2899-2903.
24. Otten HG, van Ginkel WG, Hagenbeek A, Petersen EJ. Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia. Leukemia 2004; 18: 1401-1405.
25. Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol Cell Biol 2000; 20 3274-3285.
26. Agre P, Johnson PF, McKnight SL. Cognate DNA binding specificity retained after leucine zipper exchange between GCN4 and C/EBP. Science 1989; 246: 922-926.
27. Heckman CA, Mehew JW, Boxer LM. NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002; 21: 3898-3908.
28. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995; 80: 321-330.
29. Watanabe D, Suda T, Nagata S. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int Immunol 1995; 7: 1949-1956.
30. Oelgeschlager M, Nuchprayoon I, Luscher B, Friedman AD. C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol 1996; 16: 4717-4725.
31. Stein B, Cogswell PC, Baldwin Jr AS. Functional and physical associations between NF-κB and C/EBP family members: A Rel domain-bZIP interaction. Mol Cell Biol 1993; 13: 3964-3974.
32. Stein B, Baldwin Jr AS. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-κB. Mol Cell Biol 1993; 13: 7191-7198.
33. Hu HM, Tian Q, Baer M, Spooner CJ, Williams SC, Johnson PF et al. The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1. J Biol Chem 2000; 275: 16373-16381.
34. Kim H, Whartenby KA, Georgantas III RW, Wingard J, Civin CI. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells 2002; 20: 174-182.
35. Dutton A, O'Neil JD, Milner AE, Reynolds GM, Starczynski J, Crocker J et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 2004; 101: 6611-6616.
36. Thomas RK, Kallenborn A, Wickenhauser C, Schultze JL, Draube A, Vockerodt M et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 2002; 160: 1521-1528.
37. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106: 1801-1807.
38. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004; 64: 7086-7091.
39. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. The genomic landscape of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
40. Zahnow CA, Younes P, Laucirica R, Rosen JM. Overexpression of C/ EBPβ-LIP a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 1997; 89: 1887-1891.
41. Ditsworth D, Zong WX. NF-κB: Key mediator of inflammation-associated cancer. Cancer Biol Ther 2004; 3: 1214-1216.